Guideline-based Pacing Therapy for Reflex Syncope
Launched by GRUPPO ITALIANO MULTIDISCIPLINARE PER LO STUDIO DELLA SINCOPE · Jan 12, 2012
Trial Information
Current as of June 19, 2025
Completed
Keywords
ClinConnect Summary
Background Divergence of opinion exists regarding the efficacy of cardiac pacing in patients affected by different forms of reflex syncope.
Definitions.
Severe syncope is defined when:
* it is perceived by patient that it alters his/her quality of life, and
* is unpredictable because occurs without, or with very short prodromes \< 10 sec (thus exposing patients to risk of trauma) or, if preceded by prodromes, syncope recurs despite appropriate therapies (CPM or drugs).
Recurrent syncopes: at least 2 episodes during the last year (including the index episode) or 3 episodes during the las...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients affected by severe, recurrent, certain or suspected (undetermined) reflex syncopes, aged ≥ 40 years.
- Exclusion Criteria:
- • Reflex syncopes due to reversible causes, e.g., vasoactive drugs, concomitant diseases, etc
- • Suspected of certain cardiac syncope
- • Syncope caused by orthostatic hypotension
- • Non-syncopal causes of transient loss of consciousness
About Gruppo Italiano Multidisciplinare Per Lo Studio Della Sincope
The Gruppo Italiano Multidisciplinare per lo Studio della Sincope (GIMSS) is a leading clinical research organization dedicated to advancing the understanding and management of syncope through multidisciplinary collaboration. Comprising a network of experts from various medical specialties, GIMSS focuses on conducting innovative clinical trials, fostering research initiatives, and disseminating findings to improve patient outcomes. With a commitment to rigorous scientific methodology and ethical standards, GIMSS aims to enhance the clinical landscape of syncope by developing evidence-based guidelines and promoting best practices in diagnosis and treatment.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Reggio Emilia, , Italy
Firenze, , Italy
Bolzano, , Italy
Catania, , Italy
Empoli, , Italy
Firenze, , Italy
Lavagna, , Italy
Taranto, , Italy
Patients applied
Trial Officials
Michele Brignole, MD
Principal Investigator
Ospedali del Tigullio, Lavagna, Italy
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials